Josh Makower is the Founder and Chief Executive Officer of ExploraMed, a medical device incubator. He is also a Venture Partner with New Enterprise Associates, where he supports the investing activity in the medical device arena.

In addition, Dr. Makower is Co-founder of Stanford's Biodesign Innovation Program, and a Consulting Associate Professor of Medicine at the Stanford University Medical School.

Makower has founded several companies through the ExploraMed incubator, including Acclarent, Inc., a company focused on developing novel therapies in ENT, which was acquired by J&J in 2010; TransVascular, Inc., a company focused on the development of a completely catheter-based coronary bypass technology, which was acquired by Medtronic, Inc. in 2003; and EndoMatrix, Inc., a company focused on the development of a novel therapy for incontinence and GI Reflux, which was acquired by C.R. Bard in 1997. Up until 1995, Makower was Founder and Manager of Pfizer's Strategic Innovation Group, a group chartered to create new medical device technologies and businesses.

Makower also serves on the Board of Directors for NeoTract, Inc,, Moximed, Inc., Intrinsic Therapeutics, Inc., ExploraMed III, Inc,. and Vibrynt, Inc. He also holds over five dozen patents for various medical devices in the fields of Orthopedics, ENT, Cardiology, General Surgery, Drug Delivery and Urology.

Dr. Makower holds an M.B.A. from Columbia University, an M.D. from the New York University School of Medicine, and an S.B. in Mechanical Engineering from the Massachusetts Institute of Technology.

Related Links: http://exploramed.com/index.html   

Last Updated: Wed, May 19, 2010